Anti-NGF antibodies and methods using same
First Claim
Patent Images
1. An anti-nerve growth factor (NGF) antibody wherein said antibody:
- (a) binds NGF with a KD of less than about 2 nM;
(b) inhibits human NGF-dependent survival of mouse E13.5 trigeminal neurons with an IC50 of about 100 pM or less, wherein the IC50 is measured in the presence of about 15 pM human NGF; and
(c) inhibits human NGF-dependent survival of mouse E13.5 trigeminal neurons with an IC50 of about 10 pM or less, wherein the IC50 is measured in the presence of about 1.5 pM of human NGF.
0 Assignments
0 Petitions
Accused Products
Abstract
The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
-
Citations
33 Claims
-
1. An anti-nerve growth factor (NGF) antibody wherein said antibody:
-
(a) binds NGF with a KD of less than about 2 nM;
(b) inhibits human NGF-dependent survival of mouse E13.5 trigeminal neurons with an IC50 of about 100 pM or less, wherein the IC50 is measured in the presence of about 15 pM human NGF; and
(c) inhibits human NGF-dependent survival of mouse E13.5 trigeminal neurons with an IC50 of about 10 pM or less, wherein the IC50 is measured in the presence of about 1.5 pM of human NGF. - View Dependent Claims (2, 3, 4, 5, 31, 32, 33)
-
-
6. An antibody comprising a heavy chain variable region comprising:
-
(a) a CDR1 region of SEQ ID NO;
9, wherein I34 is S, L, V A, or I; and
N35 is substituted with N, T or S;
(b) a CDR2 region of SEQ ID NO;
10, wherein M50 is I, G, Q, S, or L;
A62 is A, or S; and
L63 is L or V; and
(c) a CDR3 region of SEQ ID NO;
11, wherein Y100 is Y, L, or R;
wherein Y101 is Y or W;
wherein G103 is G, A, or S;
wherein T104 is T or S;
wherein S105 is S, A, or T;
wherein Y106 is Y, R, T, or M;
wherein Y107 is Y or F;
wherein F108 is F or W;
wherein D109 is D, N, or G; and
wherein Y110 is Y, K, S, R or T;
wherein the antibody binds NGF. - View Dependent Claims (7)
-
-
8. An antibody comprising a light chain variable region comprising:
-
(a) a CDR1 region of SEQ ID NO;
12, wherein S26 is S or F;
D28 is D, S, A, or Y; and
H32 is H, N, or Q;
(b) a CDR2 region of SEQ ID NO;
13, wherein I51 is I, T, V or A; and
S56 is S or T; and
(c) a CDR3 region of SEQ ID NO;
14, wherein K92 is K, H, R, or S; and
wherein Y96 is Y or R;
wherein the antibody binds NGF. - View Dependent Claims (9)
-
-
10. An antibody comprising (a) a heavy chain variable region comprising:
-
(i) a CDR1 region of SEQ ID NO;
9, wherein I34 is substituted with S, L, V A, or I; and
N35 is substituted with N, T or S;
(ii) a CDR2 region of SEQ ID NO;
10, wherein M50 is I, G, Q, S, or L;
A62 is A, or S; and
L63 is L or V; and
(iii) a CDR3 region of SEQ ID NO;
11, wherein Y100 is Y, L, or R;
wherein Y101 is Y or W;
wherein G103 is G, A, or S;
wherein T104 is T or S;
wherein S105 is S, A, or T;
wherein Y106 is Y, R, T, or M;
wherein Y107 is Y or F;
wherein F108 is F or W;
wherein D109 is D, N, or G;
wherein Y110 is Y, K, S, R or T; and
(b) a light chain variable region comprising;
(i) a CDR1 region of SEQ ID NO;
12, wherein S26 is S or F;
D28 is D, S, A, or Y; and
H32 is H, N, or Q;
(ii) a CDR2 region of SEQ ID NO;
13, wherein I51 is I, T, V or A; and
S56 is S or T; and
(iii) a CDR3 region of SEQ ID NO;
14, wherein S91 is S or E;
K92 is K, H, R, or S; and
wherein Y96 is Y or R;
wherein the antibody binds NGF. - View Dependent Claims (11, 12, 13, 14, 15, 16)
-
-
17. An antibody comprising a heavy chain variable region comprising:
-
(a) a CDR1 region shown in SEQ ID NO;
3;
(b) a CDR2 region shown in SEQ ID NO;
4; and
(c) a CDR3 region shown in SEQ ID NO;
5;
wherein the antibody binds NGF. - View Dependent Claims (18, 28, 29, 30)
-
-
19. An antibody comprising a light chain variable region comprising:
-
(a) a CDR1 region shown in SEQ ID NO;
6;
(b) a CDR2 region shown in SEQ ID NO;
7; and
(c) a CDR3 region shown in SEQ ID NO;
8;
wherein the antibody binds NGF. - View Dependent Claims (20, 21, 22, 23, 24, 25, 26, 27)
-
Specification